Moxifloxacin Injection shortage
Moxifloxacin Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.
Fresenius Kabi is stopping production of moxifloxacin injection 400 mg/250 mL, and this change may be permanent. The same strength is still listed by Fresenius Kabi outside the shortage report, but no manufacturer currently shows an available supply.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Moxifloxacin Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Oct 29, 2025Currently in shortage1 of 1 product affected.
-
Oct 29, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Moxifloxacin Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Moxifloxacin Injection? options further down this page.
Why is Moxifloxacin Injection in shortage?
Fresenius Kabi USA is permanently stopping production of their specific version of moxifloxacin injection — the 400 mg per 250 mL bag (NDC 63323-850-74). They didn't share a specific public reason for this decision, just that they are discontinuing the manufacturing of this product altogether.
It's worth knowing that this report only covers what Fresenius Kabi filed with the FDA — it's about their particular product, not necessarily every version of this medication that exists. Other manufacturers may produce their own versions and are tracked separately.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Moxifloxacin Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Moxifloxacin Injection?
Moxifloxacin Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The strength involved is 400mg per 250mL, and right now this is the only strength covered by this report. There is no available source listed for it at this time. The reason given is that the manufacturer, Fresenius Kabi USA, is discontinuing production of this product. Because the status is listed as "to be discontinued," this supply problem may be permanent rather than temporary, so a conversation with your prescriber is the right next step.
Please keep in mind this information comes from national, manufacturer-reported FDA data. It may not match what your local pharmacy actually has on its shelves.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check with wholesalers and other suppliers — the same medicine in this strength is also listed under Fresenius Kabi, and your pharmacy may be able to source it, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Moxifloxacin Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Moxifloxacin Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Moxifloxacin | MOXIFLOXACIN HYDROCHLORIDE 400 mg/250mL | Injection, Solution · Intravenous | Fresenius Kabi USA, LLC | 63323-0850-04 |
Therapeutic equivalents & pricing 3 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Moxifloxacin 400 mg/250mL | Fresenius | 250 ml | — | — | FDA listed |
| Moxifloxacin 400 mg/250mL | Hp | 250 ml | — | — | FDA listed |
| Moxifloxacin Hydrochloride 400 mg/250mL | Mylan | 250 ml | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Moxifloxacin Injection — that fall in the same broad treatment class (quinolone antibiotics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other anti-infective shortages
Moxifloxacin Injection shortage FAQs
Is Moxifloxacin Injection in shortage?
Which products are affected?
When will Moxifloxacin Injection be available again?
Can I still get Moxifloxacin somewhere?
What should I do if I take Moxifloxacin Injection?
Still have a question about the Moxifloxacin Injection shortage?
Ask a pharmacist about this shortage →View Moxifloxacin Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.